Under the epidemic prevention and control, Beijing Life Science Industrial Park set off a wave of development

In 2022, among the more than 100 A-share companies with a market value of over 100 billion, life science companies will occupy the third place, second only to the financial and liquor sectors. Looking at the Science and Technology Innovation Board alone, only 15 life science companies have landed in China three years ago, but now this number will exceed 100, with a total market value of more than 8 trillion yuan.

Focusing on Beijing, after the outbreak of the new crown pneumonia epidemic in 2020, various small and medium-sized pharmaceutical start-up companies began to be registered and established, and the number of pharmaceutical production and operation enterprises surged. Since July 2020, there have been 259 new drug manufacturers in Beijing, while only 7 companies were registered before that. At the same time, after the establishment of the Beijing Stock Exchange in 2021, among the first batch of 81 companies listed, there are 10 "specialized, special and new" companies in the field of life sciences.

According to the "Beijing's "14th Five-Year Plan" Period High-tech Industrial Development Plan", the target of the pharmaceutical and health industry in 2025 will achieve an operating income of 1 trillion yuan. Compared with the total revenue of 220 billion yuan in 2021, the industry scale of life sciences It has to be more than quadrupled. Administrative regions such as Changping and Daxing, as well as the Beijing Economic and Technological Development Zone, have released a series of policy dividends. Enterprises with major projects or breakthroughs in core technologies can receive tax reductions, rent subsidies or/and financial incentives, up to a maximum of 300 million yuan.?